Nebius shares jumped 17% after Nvidia revealed a 9.3% stake in the AI infrastructure company. The Amsterdam-based neocloud provider has become a major beneficiary of the artificial intelligence boom, with its stock rising nearly 250% over the past year. Nvidia and Nebius are partnering on AI infrastructure, including computing systems, data centers, and AI factory development. The company has also secured major agreements, including a … Continue reading Nebius stock surges 17% as Nvidia discloses significant stake in neocloud

A federal judge approved a $1.5 billion settlement requiring AI company Anthropic to compensate authors whose books were used without permission to train its Claude chatbot. More than 482,000 books are covered by the agreement, with authors and publishers receiving about $3,000 per claimed work. The settlement follows a ruling that found AI training itself may qualify as fair use, but Anthropic improperly obtained millions … Continue reading Judge approves a $1.5B Anthropic settlement over pirated books used to train the Claude

Novo Nordisk, the maker of Wegovy and Ozempic, has sued rival Eli Lilly over claims that its advertising falsely suggests Lilly’s weight-loss drugs are more effective. The lawsuit alleges Eli Lilly used outdated comparisons that favored Mounjaro and Zepbound over lower doses of Novo Nordisk’s treatments while leaving out newer data. Eli Lilly denied the accusations, saying its advertising is accurate, transparent, and based on … Continue reading Ozempic-maker accuses rival of false advertising

Netflix reported second-quarter earnings that were slightly above expectations for profit but narrowly missed revenue estimates. The company posted $12.56 billion in revenue, a 13% increase from the previous year, driven by subscriber growth, higher prices, and rising advertising revenue. Net income increased to $3.40 billion compared with $3.13 billion a year earlier. Despite the solid results, Netflix shares fell more than 7% as investors … Continue reading Netflix stock falls as earnings forecast disappoints

Samsung Biologics announced a $1.8 billion all-cash offer to acquire Switzerland’s PolyPeptide Group, a company specializing in peptide-based pharmaceutical ingredients. The deal would be the largest biopharmaceutical acquisition in South Korea’s history and is expected to close by the end of the year. The acquisition aims to expand Samsung Biologics’ portfolio beyond antibody drugs into fast-growing peptide therapies, including treatments for obesity and diabetes. PolyPeptide … Continue reading Samsung Biologics makes $1.8 billion all-cash offer for Switzerland’s PolyPeptide Group